Mechanizm działania etorykoksybu i diklofenaku w bólu zapalnym Artykuł przeglądowy

##plugins.themes.bootstrap3.article.main##

Agnieszka Sękowska
Małgorzata Malec-Milewska

Abstrakt

NLPZ są jednymi z najczęściej stosowanych leków w farmakoterapii bólu. Mechanizm działania NLPZ związany jest przede wszystkim z zahamowaniem syntezy prostaglandyn, pośredniczących w rozwoju stanu zapalnego, co ma priorytetowe znaczenie w leczeniu bólu o podłożu zapalnym. Diklofenak to lek pierwszego wyboru w ChZS oraz w spondyloartropatiach. Etorykoksyb, stosunkowo nowy na rynku polskim NLPZ, jest lekiem z wyboru w leczeniu objawowym ChZS, ZZSK, RZS, napadu dny moczanowej, ostrego bólu po wymianie stawu biodrowego [1–5].

##plugins.themes.bootstrap3.article.details##

Jak cytować
Sękowska , A., & Malec-Milewska , M. (2020). Mechanizm działania etorykoksybu i diklofenaku w bólu zapalnym . Kardiologia W Praktyce, 14(3-4), 34-37. Pobrano z https://www.journalsmededu.pl/index.php/kwp/article/view/1166
Dział
Farmakologia kliniczna w praktyce

Bibliografia

1. National Institute for Health and Care Excellence. Low back pain and sciatica in over 16s: assessment and management. NICE guideline [NG50], 2016. Online: https://www.nice.org.uk/guidance/ng59.
2. van der Heijde D, Ramiro S, Landewé R et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017; 76: 978-91.
3. Combe B, Landewe R, Daien CI et al. 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis. 2017; 76: 948-59.
4. McAlindon E, Bannuru RR, Sullivan MC et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014; 22: 363-88.
5. Online: http://www.ema.europa.eu.
6. Chan CC, Boyce S, Brideau C et al. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: A novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther. 1995; 274: 1531-7.
7. Riendeau D, Percival MD, Brideau C et al. Etoricoxib (MK-0663): Preclinical Profile and Comparison with Other Agents That Selectively Inhibit Cyclooxygenase-2. J Pharmacol Exp Ther. 2001; 296: 558-66.
8. Renner B, Zacher J, Buvanendran A et al. Absorption and distribution of etoricoxib in plasma, CSF, and wound tissue in patients following hip surgery – a pilot study. Naunyn-Schmied Arch Pharmacol. 2010; 381: 127-36.
9. Arendt-Nielsen L, Egsgaard LL, Petersen KK. Evidence for a central mode of action for etoricoxib (COX-2 inhibitor) in patients with painful knee osteoarthritis. Pain. 2016; 157: 1634-44.
10. Ghanghas P, Jain S, Rana C et al. Chemoprevention of Colon Cancer through Inhibition of Angiogenesis and Induction of Apoptosis by Nonsteroidal Anti-Inflammatory Drugs. J Environ Pathol Toxicol Oncol. 2016; 35: 273-89.
11. Nadda N, Vaish V, Setia S et al. Angiostatic role of the selective cyclooxygenase-2 inhibitor etoricoxib (MK0663) in experimental lung cancer. Biomed Pharmacother. 2012; 66: 474-83.
12. Citraro R, Leo A, Marra R et al. Antiepileptogenic effects of the selective COX-2 inhibitor etoricoxib, on the development of spontaneous absence seizures in WAG/Rij rats. Brain Res Bull. 2015; 113: 1-7.
13. Burmester G, Lanas A, Biasucci L et al. The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann Rheum Dis. 2011; 70: 818-22.
14. Coxib and traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013; 382: 769-79.
15. Cannon CP, Curtis SP, FitzGerald GA et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006; 368: 1771-81.
16. van Walsem A, Pandhi S, Nixon RM et al. Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis. Arthritis Res Ther. 2015; 17: 66.
17. Tielemans MM, Eikendal T, Jansen JB et al. Identification of NSAID users at risk for gastrointestinal complications: a systematic review of current guidelines and consensus agreements. Drug Saf. 2010; 33: 443-53.
18. Moore RA, Moore OA, Derry S et al. Responder analysis for pain relief and numbers needed to treat in a metaanalysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Ann Rheum Dis. 2010; 69: 374-79.